Compugen: What Is Really Left in Rilvegostomig After the AstraZeneca Amendment
The main article showed that AstraZeneca's cash bought Compugen time. This follow-up shows that the amendment did not erase all of rilvegostomig's upside: common shareholders still retain a large milestone layer and the majority of the royalty layer, but what remains is narrower, more AstraZeneca-dependent, and less transparent than before.
The Cash Was Pulled Forward, but the Tail Was Not Eliminated
The main article argued that AstraZeneca's cash bought Compugen time, not proof of value. This follow-up isolates the question left behind after the $65 million received in December 2025: how much of rilvegostomig's economics still belongs to common shareholders after the amendment.
The short answer is that the value was not wiped out, but it is no longer the same value mix. The amendment pulled part of the economics forward into immediate cash, added $25 million to the next milestone tied to the first BLA acceptance, and still leaves Compugen eligible for up to $195 million of future regulatory and commercial milestones together with the majority of the royalty layer at tiered rates of up to mid-single digit. At the same time, the company does not disclose what exact slice of royalties was sold, no royalties have yet been recognized because there were still no net sales at year-end, and what remains now depends even more heavily on AstraZeneca's clinical, regulatory, and commercial execution.
That is the core point. The amendment did not kill the upside. It changed its shape. Instead of leaning mainly on a distant royalty tail, part of the value has already been turned into cash, while another part has been shifted toward regulatory gates and future milestones. Common shareholders still own meaningful rilvegostomig economics, but in a narrower, more partner-driven, and less precisely quantifiable form.
Three points matter from the outset:
- Out of the $105.5 million Compugen has already received from AstraZeneca since signing the agreement, $65 million arrived only in the December 2025 amendment. Most of the value already realized from this asset was therefore pulled forward only now.
- The amendment did not wipe out the milestone layer. Even after the amendment, the company still speaks about up to $195 million of future regulatory and commercial milestones, including the added $25 million on the first BLA acceptance.
- Exactly as the economics become more concentrated in one partnered asset, Compugen itself says COM902 now has only limited near-term value, that it does not plan to initiate new clinical trials with COM902, and that the recent TIGIT failures may also be reflected in rilvegostomig trials.
That chart sharpens an easy-to-miss point. The December 2025 payment alone was larger than everything that came before it combined. Between 2018 and 2024, Compugen received $40.5 million from AstraZeneca. The amendment added another $65 million in one step. So the right reading is not simply that the company sold part of a future right. The stronger reading is that it accelerated a large part of the value it was able to lock in today.
That is also why the main article focused on liquidity. In 2025, revenue totaled about $72.8 million, and the company explicitly said that this included the $65 million upfront payment from AstraZeneca. Before asking what remains in the future, investors need to acknowledge that a meaningful slice of the asset has already crossed from contingent value into recognized cash.
What Actually Remains After the Amendment
The easiest mistake is to read the partial royalty sale as if only a thin residual stub remains for common shareholders. That is the wrong read. The disclosure describes a more layered picture.
| Layer | What the disclosure does say | What it means economically |
|---|---|---|
| Immediate cash | $65 million was paid in December 2025 | A meaningful part of the asset is no longer contingent on trial results, approval, or sales |
| Next gate | $25 million was added to the next milestone tied to first BLA acceptance | Part of the value was moved from the long tail toward a clearer regulatory gate |
| Future milestones | Up to $195 million of future regulatory and commercial milestones | The milestone layer remains material even after the amendment |
| Royalties | Compugen retained the majority of the royalty layer, at tiered rates of up to mid-single digit | The royalty tail still exists, but it is smaller and less transparent |
| Royalties recognized | None as of year-end 2025 because there were no net sales | Economically, the sales phase has not begun yet |
Two analytical conclusions follow.
First: the amendment looks much less like a full sale of the future and much more like a rebalancing between immediate cash, milestones, and royalties. Anyone focusing only on the sale of part of the royalty stream misses the fact that the company kept both a large milestone layer and the majority of the royalty layer.
Second: even though the company says the majority remains with it, it does not provide the one number investors really need, the exact portion of the royalty stream that was sold. Without that, one can understand the direction of the change, but not build a clean value bridge for the royalty layer that remains.
The second chart matters for the same reason. It does not include the royalty layer, because the company itself does not disclose enough to quantify it after the amendment. But even without royalties, the picture is clear: Compugen has already realized $105.5 million in upfront and milestone cash from AstraZeneca, and it still keeps a future milestone layer of up to $195 million. That makes it difficult to describe this deal as a full surrender of upside.
There is also an accounting note here with real economic importance. The company says explicitly that royalties are recognized only when there are net sales, and as of year-end 2025 no royalty revenue had been recognized. So the remaining royalty layer is not cash sitting just around the corner. It is still a commercial option on sales that have not started yet.
Why the Remaining Value Is More Fragile Than the Headline Suggests
If the amendment had arrived into a strong TIGIT field, with internal COM902 optionality still moving forward, the remaining economics could have looked like a relatively comfortable residual upside story. That is not the backdrop here.
Compugen says in unusually direct language that COM902, after showing certain early signals of antitumor activity, now has only limited potential to create near-term value for the company. The stated reason is the recent negative data in TIGIT, especially the December 2025 Arcus and Gilead announcement that the Phase 3 STAR-221 study would be discontinued due to futility. On that basis, the company says it does not plan to initiate new clinical trials with COM902 for now.
That materially changes how the remaining rilvegostomig economics should be read. By the end of 2025, Compugen no longer really holds a broad basket of TIGIT optionality. It mostly holds one asset, rilvegostomig, fully developed by AstraZeneca and dependent on AstraZeneca clinically, regulatorily, and commercially.
The company reinforces that read in two more places. On the one hand, it says rilvegostomig is being evaluated across multiple Phase 3, Phase 2, and Phase 1 trials. On the other hand, it warns that the recent TIGIT failures may also be reflected in rilvegostomig trials, and that if major safety issues, lack of efficacy, or termination of the AstraZeneca collaboration were to occur, the effect on Compugen could be material. It also notes that AstraZeneca may terminate the agreement for convenience upon prior written notice.
That means the remaining upside is not only smaller in the royalty layer. It now sits deeper inside the partner. AstraZeneca is solely responsible for the research, development, and commercial activities under the agreement. Compugen retains an economic right, not operating control.
There is one more tension here that matters. In the same disclosure, the company reminds investors that in 2024 AstraZeneca provided a non-risk-adjusted peak year revenue target for rilvegostomig of over $5 billion. That is exactly why the sale of part of the royalty stream is such a material issue. But the same 20-F also warns that the TIGIT field has weakened and that the recent failures may spill over here as well. So the old more than $5 billion anchor cannot be used today as a shortcut to valuation. It only explains why the royalty layer still matters, not why it should be valued aggressively.
| What still supports the remaining value | What weighs on the read |
|---|---|
| Rilvegostomig is still active across multiple Phase 3, Phase 2, and Phase 1 trials | Recent TIGIT failures make even the lead asset less clean than before |
| The next milestone was sweetened by $25 million at first BLA acceptance | The timing of that milestone still depends on regulatory progress outside Compugen's control |
| The majority of the royalty layer remains with Compugen | The company does not disclose what exact portion was sold, making the retained layer hard to quantify |
| AstraZeneca previously framed very high peak sales potential | As of year-end 2025 there were still no net sales, so there is still no royalty economics in practice |
That is the heart of this continuation. Common shareholders were not left without rilvegostomig. They were left with a real economic asset. But that asset changed in three ways at once: part of it became cash already, part of it became more concentrated around a specific regulatory gate, and the longer-dated part became more dependent on a weaker TIGIT field and on AstraZeneca's decisions.
The Bottom Line
The correct reading of the amendment is not that Compugen exited rilvegostomig, but it is also not that nothing material changed. Both views miss the actual shift.
What did happen is this: Compugen locked in $65 million of cash, made the next milestone fatter, kept a meaningful future milestone layer and the majority of the royalty layer, but gave up part of the tail without telling investors exactly how much. Common shareholders therefore still retain real upside, but it is now narrower, less transparent, and more dependent on AstraZeneca's ability to take rilvegostomig through approval and sales in a TIGIT field that already looks less forgiving.
The practical meaning is that what remains after the amendment is no longer a broad platform bet. It is a more concentrated bet on one partnered asset. The 2025 cash already belongs to shareholders. The future milestones and royalty layer do not. Anyone reading the amendment as a full exit is wrong, and anyone reading it as if the royalty story were basically unchanged is also wrong.
Disclosure: Deep TASE analyses are general informational, research, and commentary content only. They do not constitute investment advice, investment marketing, a recommendation, or an offer to buy, sell, or hold any security, and are not tailored to any reader's personal circumstances.
The author, site owner, or related parties may hold, buy, sell, or otherwise trade securities or financial instruments related to the companies discussed, before or after publication, without prior notice and without any obligation to update the analysis. Publication of an analysis should not be read as a statement that any position does or does not exist.
The analysis may contain errors, omissions, or information that changes after publication. Readers should review official filings and primary sources before making decisions.